 David, your commercial relationship with SEVA and Sona Nanotech, what's happening with that deal presently? Gracie, this is a deal that was announced last fall between ourselves, Sona Nanotech, which is a manufacturer of a uniquely biocompatible Gold Nano Rods and SEVA Therapeutics of the US that is pursuing the development of a certain type of photothermal therapy for using Gold Nano Rods for cancer treatment. We're a strategic supplier to them. That was announced back in October. In the time since then, one of the first steps we've undertaken is to have batches of our Gold Nano Rods sent to the Nanotechnology Characterization Laboratory in the US, which was founded by the FDA and the Cancer Institute of the US, and from which SEVA Therapeutics received a prestigious grant to do work and analysis on Gold Nano Rods associated with their therapy. That's something, that's work that's ongoing, a vetting, if you will, of our materials and a characterization of our materials with a view to moving both parties forward towards SEVA's therapy for cancer treatment. And of course, Sona Nanotech has a nanotechnology that is specifically used in treatment and facilitating the treatment of some of the top ranked cancer issues that we're dealing with. You want to start with what you're prioritizing presently. Sure. So Sona makes biocompatible Gold Nano Rods. Historically, we've used them for the development of rapid tests. We've got a few prototypes that are coming along nicely now, but the thrust going forward for the companies and using those Gold Nano Rods for nanomedical applications. SEVA is our first partner in that area. Their focus is on heating tumors from the inside out using Gold Nano Rods, and the first application will be for colorectal cancer. This is a cancer that's the second most mortal in the world. It's a prime candidate for this type of therapy because it can be accessed with the LED light source they use to heat the tumor and the Gold Nano Rods from the inside out. And what is your update on your patent process with your technology? A great question. That's something that's coming along. I regularly asked our patent council the same thing. When I grow frustrated, it is to the length of time it's taking, and she does a great job in assuring me as to that this process does take a while and that we are tracking nicely towards it. Obviously, the US is the focus, but we're looking to protect the patent, the technology much more broadly than that. It's a process by which the patent application can be challenged from all quarters and we've received many challenges on it and we've been able to overcome them all and continue moving. I don't have a target date for it, but it is in the works and we will eventually get it. And of course, you understand setting up the foundation of a successful company. We've seen announcements over the last year for the addition of new team members. Would you like to talk about some of your board members and how they can help you achieve these goals in 2023 and moving forward? Sure. Tracy is a precursor to moving towards into the into the nanomedical area. We were fortunate to attract to our board one of Vinod Kosla's biotech CEOs, Dr. Walter Straps, who leads a Cas9, Jean Crisper biotech company out of Boston. We were also able to attract Mr. Neil Frazier, who's the longtime president of Medtronic Canada, leading device developer manufacturer worldwide. I think it's that $30 billion company headquartered in Minneapolis. Obviously, both of those backgrounds are extremely relevant to what it is we're doing now. We're also fortunate to have other representation on the board from Mark LeVonnen, who's a longtime CEO of Sanofi Pasteur, as well as of other individuals with venture capital and fundraising experience and medical experience. So we feel we're really, really well endowed at the board level. And that helped to set up the partnership with SIVA and understanding of our our push into nanomedical applications. But as I say, as I've said previously, it's not just SIVA. There'll be other partners, there'll be other applications. This is the one, this is a bit of a beachhead partnership we formed with them. We think they've got, they'll have good momentum going forward with this first application and that the concept will spread from there and will be the provider of choice to developers of photothermal therapies for nanomedical purposes. Well, David, thank you so much for, for doing an interview and providing an update on Sona Nanotech. And for those of you interested in more information, please go to their website. David, thank you. Thank you, Tracy. Always happy to talk.